Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Oct sc depot is a novel, ready to use formulation administered via a thin needle.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Pavel M, Borson-Chazot , Hörsch D, Lahner , Pivonello R,
Keywords: octreotide sc depot, NET,
Introduction: The mTOR pathway and dopamine receptors are potential targets for treatment of neuroendocrine tumors (NET).
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author: Sarnataro M
Authors: Sarnataro M, Pivonello C, De Martino M, Sciammarella C, Cuomo G,
Introduction: The mammalian target of rapamycin (mTOR) is a protein kinase involved in the control of cancer cell metabolism, growth and proliferation. The mTOR pathway has attracted broad scientific and clinical interest, particularly in light of the ongoing clinical cancer trials with mTOR inhibitors in pts with neuroendocrine tumors (NETs). To identify the best candidates for treatment with mTOR inhibitors is challenging.
Conference: 10th Annual ENETSConcerence (2013)
Presenting Author:
Authors: Sciammarella C, Pivonello C, Sarnataro M, Marotta V, Ramundo V,
Keywords: mTOR pathway, everolimus, pancreatic NET, bronchial carcinoids,
Introduction: The mTOR inhibitor rapamycin (RAP) has been considered an anticancer agent. The role of dopamine and somatostatin in controlling cell secretion and proliferation in neuroendocrine tumors (NETs) is still unclear.
Conference: 9th Annual ENETSConcerence (2012)
Presenting Author:
Authors: Pivonello R, Sarnataro M, Cariati F, Pivonello C, Colao A,
Keywords: neuroendocrine tumor, mTOR inhibitors, dopamine agonists, somatostatin analogues,
Introduction: Medullary thyroid carcinoma (MTC) accounts for approximately 5-10% of thyroid cancers. In the case of tumors limited to the thyroid gland, the prognosis is generally favorable, whereas 5-year survival averages only 40% in patients with metastatic disease. In these patients, conventional chemotherapy only occasionally leads to a complete response and partial responses are observed in less than 30% of the cases. Therefore, intense efforts are currently directed toward the identification of new druggable targets for the treatment of this devastating disease.
Conference: 7th Annual ENETSConcerence (2010)
Presenting Author: Pivonello R
Authors: Pivonello R, Pivonello C, Cavaccini A, Petrillo G, De Marino G,
Keywords: medullary thyroid carcinoma, T-type calcium channels, mibefradil, calcitonin, apoptosis,